About Lunch Webinar Discussion 'Why invest in Healthcare Innovations?'

Are we entering a ‘golden era’ of health care innovation? Breakthroughs in genomic sequencing and data processing are enabling highly targeted and precise interventions. Biopharma appears to be in the midst of this wave of innovation.

At the same time, biopharmaceutical innovations are coinciding with lightning-fast developments in AI. Together they are paving the way for new treatments for far-reaching diseases worldwide, such as obesity and other chronic metabolic diseases. 

• How do technological innovations in healthcare translate into investment opportunities?
• What are the risks?
• How is AI driving innovation and developments within the sector?
• What kind of companies are set to benefit in the long term?
• How to approach the sector in your investment portfolio?

On Tuesday, September 3rd, from 12 to 1 pm, Financial Investigator is hosting a Lunch Webinar Discussion on 'Why invest in Healthcare Innovations?'.

Two buy-side fund/manager will pose (critical) questions to two healthcare innovations specialists.

The questioners are

• Coos Luning, Head of Multimanagement, Aegon Asset Management
• Harry Geels, Senior Investment Advisor, Auréus

Questions will be answered by:

• Laura Nelson Carney, Investment Analyst Biotech/Pharma, Capital Group
• Steve Smith, Investment Director, Capital Group
  
  

 
Registration
Participation is open to buy-side investment professionals working at pension funds, fiduciary managers, family offices, consultants, banks, insurers or working in the field of fund selection at independent asset managers. Your registration is subject to approval by Financial Investigator and the parties making this seminar financially possible.